CDC Grants Spark Development Of Faster Flu Tests
This article was originally published in The Gray Sheet
Executive Summary
Several companies are working hard this spring and summer to develop diagnostics to accurately test patients for newly emerging dangerous flu strains and differentiate them from more garden variety versions within 30 minutes
You may also be interested in...
Most States Still Lack ‘Sentinel Labs’ For Pandemic Flu Testing – OIG Report
Most states - 44 out of 50, plus the District of Columbia - still have no sentinel lab capability to detect influenza A subtype H5, the avian flu virus that could lead to pandemic flu, despite $350 million appropriated by Congress in 2005 to help prepare for this potential catastrophe, says the HHS Office of Inspector General
Most States Still Lack ‘Sentinel Labs’ For Pandemic Flu Testing – OIG Report
Most states - 44 out of 50, plus the District of Columbia - still have no sentinel lab capability to detect influenza A subtype H5, the avian flu virus that could lead to pandemic flu, despite $350 million appropriated by Congress in 2005 to help prepare for this potential catastrophe, says the HHS Office of Inspector General
Diagnostics In Brief
Genzyme pharmacogenomics: Firm announces availability of its KRAS gene mutation analysis test to help identify 15%-30% of non-small cell lung cancer tumors unlikely to respond to treatment with drugs Tarceva (Genentech) or Iressa (AstraZeneca). The test, available only through Genzyme's lab, joins two other assays in the firm's portfolio that can conversely detect improved response rates to those drugs based on mutations in the epidermal growth factor receptor gene (1"The Gray Sheet" Oct. 3, 2005, In Brief). "This important convergence of diagnostics and therapeutics is a priority for the company," Genzyme says...